Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

CMV vaccine shows promise in Long-Term protection study

NCT ID NCT04975893

First seen Feb 02, 2026 · Last updated Apr 30, 2026 · Updated 12 times

Summary

This study looked at how long the mRNA-1647 vaccine protects against CMV infection in adults who already completed an earlier vaccine study. A small group also received a booster dose to see if it improves immunity. The goal is to understand the vaccine's long-term safety and immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alliance for Multispeciality Research, LLC

    Lexington, Kentucky, 40509, United States

  • Crossroads Clinical Research (Victoria)

    Victoria, Texas, 77901, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah, 84109, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah, 84121, United States

  • Johnson County Clin-Trials, Inc.

    Lenexa, Kansas, 66219, United States

  • Optimal Research, LLC

    Peoria, Illinois, 61610, United States

  • Tekton Research Inc

    Austin, Texas, 78745, United States

Conditions

Explore the condition pages connected to this study.